Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:indanes
go back to main search page
Accession:CHEBI:46940 term browser browse the term



show annotations for term's descendants           Sort by:
 
4-Acetyl-6-tert-butyl-1,1-dimethylindane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO acetyl tert-butyl dimethylindan binds to and results in decreased activity of AR protein CTD PMID:17762842 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO acetyl tert-butyl dimethylindan binds to and results in increased activity of ESR1 protein CTD PMID:17762842 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
aprindine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace2 angiotensin I converting enzyme 2 increases activity ISO Aprindine results in increased activity of ACE2 protein CTD PMID:21859683 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Cat catalase decreases expression ISO Aprindine results in decreased expression of CAT protein CTD PMID:1937386 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Drd1 dopamine receptor D1 affects binding ISO Aprindine binds to DRD1 protein CTD PMID:9808703 NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
JBrowse link
G Drd2 dopamine receptor D2 affects binding ISO Aprindine binds to DRD2 protein CTD PMID:9808703 NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO Aprindine results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 affects response to substance ISO KCNQ1 gene affects the susceptibility to Aprindine CTD PMID:15028050 NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
JBrowse link
bromindione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO bromindione inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] CTD PMID:23769903 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
enrasentan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ednra endothelin receptor type A multiple interactions ISO enrasentan binds to and results in decreased activity of EDNRA protein CTD PMID:16219361 NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO enrasentan binds to and results in decreased activity of EDNRB protein CTD PMID:16219361 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
JBrowse link
fluindione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Vkorc1 vitamin K epoxide reductase complex, subunit 1 decreases activity
multiple interactions
ISO fluindione results in decreased activity of VKORC1 protein
fluindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide]
CTD PMID:29581108 NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
JBrowse link
G Vkorc1l1 vitamin K epoxide reductase complex, subunit 1-like 1 multiple interactions
decreases activity
ISO fluindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide]
fluindione results in decreased activity of VKORC1L1 protein
CTD PMID:29581108 NCBI chr12:26,717,959...26,768,193 JBrowse link
ICI 118551 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO ICI 118551 inhibits the reaction [Formoterol Fumarate results in decreased expression of ACTA2 protein] CTD PMID:21603974 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adrb1 adrenoceptor beta 1 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB1 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB1 protein]
[Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]
CTD PMID:9260993 PMID:14730417 PMID:19719783 NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions
affects binding
ISO
EXP
[ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased susceptibility to Nicotine; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GNAS protein; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GRK2 protein; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein]
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which affects the uptake of Levodopa; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Levodopa]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Terbutaline results in increased activity of ADRB2 protein]
ICI 118551 inhibits the reaction [[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose]; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]; ICI 118551 inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; ICI 118551 inhibits the reaction [Isoproterenol results in increased activity of ADRB2 protein]
CTD PMID:2462161 PMID:7969507 PMID:9260993 PMID:10344530 PMID:10372227 More... NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
JBrowse link
G Adrb3 adrenoceptor beta 3 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB3 protein; ICI 118551 binds to and results in increased activity of ADRB3 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB3 protein]
[Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein
CTD PMID:1682311 PMID:14730417 PMID:19719783 NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
JBrowse link
G Agt angiotensinogen multiple interactions ISO ICI 118551 inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]] CTD PMID:7843740 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Alpp alkaline phosphatase, placental multiple interactions ISO ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of ALPP mRNA] CTD PMID:16036225 NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
JBrowse link
G Arrb2 arrestin, beta 2 multiple interactions ISO ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]] CTD PMID:17925438 NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [ICI 118551 co-treated with gemcitabine] results in increased expression of BAX protein CTD PMID:21570961 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [ICI 118551 co-treated with gemcitabine] results in decreased expression of BCL2 protein CTD PMID:21570961 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Calca calcitonin-related polypeptide alpha multiple interactions EXP capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein] CTD PMID:14764656 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
JBrowse link
G Calcb calcitonin-related polypeptide, beta multiple interactions EXP capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein] CTD PMID:14764656 NCBI chr 1:168,966,465...168,970,125
Ensembl chr 1:168,966,465...168,970,125
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO ICI 118551 inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] CTD PMID:22167199 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Edn1 endothelin 1 multiple interactions ISO ICI 118551 inhibits the reaction [olodaterol results in decreased expression of EDN1 mRNA] CTD PMID:22796455 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Gnas GNAS complex locus multiple interactions
increases expression
ISO [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GNAS protein
ICI 118551 results in increased expression of GNAS protein
CTD PMID:10455254 NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 increases expression
multiple interactions
ISO ICI 118551 results in increased expression of GRK2 protein
[ICI 118551 co-treated with ADRB2 protein] results in increased expression of GRK2 protein
CTD PMID:10455254 NCBI chr 1:201,581,480...201,601,580
Ensembl chr 1:201,581,480...201,601,582
JBrowse link
G Il18 interleukin 18 multiple interactions ISO ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 mRNA]; ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 protein] CTD PMID:15178407 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il5 interleukin 5 multiple interactions ISO ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]] CTD PMID:16238794 NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
JBrowse link
G Il6 interleukin 6 multiple interactions EXP ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Terbutaline promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] CTD PMID:9688336 PMID:10525314 PMID:11096136 PMID:12619890 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 multiple interactions
decreases activity
ISO ICI 118551 results in decreased activity of [KCNH2 protein binds to KCNH2 protein]
ICI 118551 results in decreased activity of KCNH2 protein
CTD PMID:15679475 PMID:16314852 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]]
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK1 protein]]
CTD PMID:11675405 PMID:12608646 PMID:17003101 PMID:17925438 PMID:19719783 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]]
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK3 protein]]
CTD PMID:11675405 PMID:12608646 PMID:17003101 PMID:17925438 PMID:19719783 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions EXP [Dobutamine co-treated with ICI 118551] results in increased activity of MAPK9 protein CTD PMID:19719783 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression
decreases secretion
ISO ICI 118551 results in decreased expression of MMP2 mRNA; ICI 118551 results in decreased expression of MMP2 protein
ICI 118551 results in decreased secretion of MMP2 protein
CTD PMID:20424515 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression
decreases secretion
ISO ICI 118551 results in decreased expression of MMP9 mRNA; ICI 118551 results in decreased expression of MMP9 protein
ICI 118551 results in decreased secretion of MMP9 protein
CTD PMID:20424515 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression ISO ICI 118551 results in decreased expression of PPARGC1A mRNA CTD PMID:17446185 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression
multiple interactions
ISO ICI 118551 results in decreased expression of PTGS2 mRNA; ICI 118551 results in decreased expression of PTGS2 protein
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]
CTD PMID:17003101 PMID:17369603 PMID:20424515 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO ICI 118551 inhibits the reaction [Albuterol results in decreased expression of RB1 protein] CTD PMID:16446544 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Ren renin multiple interactions ISO ICI 118551 inhibits the reaction [Epinephrine results in increased activity of REN protein] CTD PMID:6314140 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]]
ICI 118551 inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
CTD PMID:9688336 PMID:10525314 PMID:10857765 PMID:11096136 PMID:11675405 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO ICI 118551 results in decreased expression of VEGFA mRNA; ICI 118551 results in decreased expression of VEGFA protein CTD PMID:20424515 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
indan-1-ol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akr1b10 aldo-keto reductase family 1 member B10 increases oxidation ISO AKR1B10 protein results in increased oxidation of 1-indanol CTD PMID:19013440 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 multiple interactions EXP [AKR1B8 protein co-treated with NADP] affects the oxidation of 1-indanol CTD PMID:18845131 NCBI chr 4:62,997,241...63,009,815 JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 increases oxidation ISO AKR1C4 protein results in increased oxidation of 1-indanol CTD PMID:8543560 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
JBrowse link
indane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity ISO indan results in decreased activity of CYP1A2 protein CTD PMID:15916432 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
Indanofan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO indanofan binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
pevonedistat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bbc3 Bcl-2 binding component 3 affects expression ISO pevonedistat affects the expression of BBC3 mRNA CTD PMID:24634471 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bcl2 BCL2, apoptosis regulator affects expression ISO pevonedistat affects the expression of BCL2 mRNA CTD PMID:24634471 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 affects expression ISO pevonedistat affects the expression of BCL2L1 mRNA CTD PMID:24634471 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 BCL2 like 11 affects expression ISO pevonedistat affects the expression of BCL2L11 mRNA; pevonedistat affects the expression of BCL2L11 protein CTD PMID:24634471 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Casp3 caspase 3 multiple interactions ISO pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22110742 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl17 C-C motif chemokine ligand 17 affects expression ISO pevonedistat affects the expression of CCL17 mRNA CTD PMID:24634471 NCBI chr19:10,202,317...10,203,768
Ensembl chr19:10,202,128...10,203,819
JBrowse link
G Ccl22 C-C motif chemokine ligand 22 affects expression ISO pevonedistat affects the expression of CCL22 mRNA CTD PMID:24634471 NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 affects expression ISO pevonedistat affects the expression of CCL5 mRNA CTD PMID:24634471 NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
JBrowse link
G Ccnd1 cyclin D1 affects expression ISO pevonedistat affects the expression of CCND1 mRNA CTD PMID:24634471 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 affects expression ISO pevonedistat affects the expression of CCND2 mRNA CTD PMID:24634471 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Cd40 CD40 molecule affects expression ISO pevonedistat affects the expression of CD40 mRNA CTD PMID:24634471 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cd74 CD74 molecule affects expression ISO pevonedistat affects the expression of CD74 mRNA CTD PMID:24634471 NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 increases abundance ISO pevonedistat results in increased abundance of CDT1 protein CTD PMID:22110742 NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression ISO pevonedistat affects the expression of CFLAR mRNA CTD PMID:24634471 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
JBrowse link
G Ctnnb1 catenin beta 1 increases abundance ISO pevonedistat results in increased abundance of CTNNB1 protein CTD PMID:22110742 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Cul1 cullin 1 decreases metabolic processing ISO pevonedistat results in decreased metabolism of CUL1 protein CTD PMID:22110742 NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980
JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 affects expression ISO pevonedistat affects the expression of CXCL9 mRNA CTD PMID:24634471 NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
JBrowse link
G Cxcr3 C-X-C motif chemokine receptor 3 affects expression ISO pevonedistat affects the expression of CXCR3 mRNA CTD PMID:24634471 NCBI chr  X:66,844,318...66,846,969
Ensembl chr  X:66,844,318...66,846,969
JBrowse link
G Cxcr5 C-X-C motif chemokine receptor 5 affects expression ISO pevonedistat affects the expression of CXCR5 mRNA CTD PMID:24634471 NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta affects expression ISO pevonedistat affects the expression of GADD45B mRNA CTD PMID:24634471 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
JBrowse link
G Hsf1 heat shock transcription factor 1 increases activity ISO pevonedistat results in increased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases abundance
multiple interactions
ISO pevonedistat results in increased abundance of JUN protein
Tretinoin promotes the reaction [pevonedistat results in increased abundance of JUN protein]
CTD PMID:22110742 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III increases expression ISO pevonedistat results in increased expression of MAF1 protein CTD PMID:31645432 NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249
JBrowse link
G Mir155hg Mir155 host gene affects expression ISO pevonedistat affects the expression of MIR155HG mRNA CTD PMID:24634471 NCBI chr11:23,773,468...23,775,697 JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO pevonedistat results in increased expression of MYC protein CTD PMID:25897075 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 affects activity ISO pevonedistat affects the activity of NFKB1 protein CTD PMID:24634471 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation ISO pevonedistat results in increased phosphorylation of NFKBIA protein CTD PMID:22110742 PMID:24634471 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO pevonedistat results in increased cleavage of PARP1 protein
pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein]
CTD PMID:22110742 PMID:24634471 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases abundance
affects expression
multiple interactions
ISO pevonedistat results in increased abundance of PMAIP1 protein
pevonedistat affects the expression of PMAIP1 mRNA
Tretinoin promotes the reaction [pevonedistat results in increased abundance of PMAIP1 protein]
CTD PMID:22110742 PMID:24634471 NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects activity ISO pevonedistat affects the activity of RELA protein CTD PMID:24634471 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rictor RPTOR independent companion of MTOR, complex 2 increases expression ISO pevonedistat results in increased expression of RICTOR protein CTD PMID:25897075 NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426
JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 increases expression ISO pevonedistat results in increased expression of RPTOR protein CTD PMID:25897075 NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
JBrowse link
G Sall4 spalt-like transcription factor 4 multiple interactions ISO pevonedistat inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein] CTD PMID:30067223 NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822
JBrowse link
G Stat5a signal transducer and activator of transcription 5A affects expression ISO pevonedistat affects the expression of STAT5A mRNA CTD PMID:24634471 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
JBrowse link
G Uba3 ubiquitin-like modifier activating enzyme 3 decreases activity ISO pevonedistat results in decreased activity of UBA3 protein CTD PMID:22110742 NCBI chr 4:129,789,526...129,810,707
Ensembl chr 4:129,789,204...129,810,606
JBrowse link
G Wee1 WEE1 G2 checkpoint kinase increases abundance ISO pevonedistat results in increased abundance of WEE1 protein CTD PMID:22110742 NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
JBrowse link
phenindione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I; [Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I metabolite CTD PMID:21613233 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Tp53 tumor protein p53 increases degradation ISO Phenindione results in increased degradation of TP53 protein CTD PMID:14634213 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Vkorc1 vitamin K epoxide reductase complex, subunit 1 decreases activity
multiple interactions
ISO Phenindione results in decreased activity of VKORC1 protein
Phenindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]
CTD PMID:29581108 NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
JBrowse link
G Vkorc1l1 vitamin K epoxide reductase complex, subunit 1-like 1 multiple interactions
decreases activity
ISO Phenindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]
Phenindione results in decreased activity of VKORC1L1 protein
CTD PMID:29581108 NCBI chr12:26,717,959...26,768,193 JBrowse link
rasagiline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gdnf glial cell derived neurotrophic factor multiple interactions
increases expression
ISO Sulfasalazine inhibits the reaction [rasagiline results in increased expression of GDNF protein]
rasagiline results in increased expression of GDNF mRNA; rasagiline results in increased expression of GDNF protein
CTD PMID:14687604 NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
JBrowse link
G Maob monoamine oxidase B decreases activity ISO rasagiline results in decreased activity of MAOB protein CTD PMID:21923181 NCBI chr  X:5,907,327...6,010,996
Ensembl chr  X:5,907,266...6,011,003
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO rasagiline results in increased localization of and results in increased activity of RELA protein; Sulfasalazine inhibits the reaction [rasagiline results in increased localization of and results in increased activity of RELA protein] CTD PMID:14687604 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19800
    chemical entity 19800
      molecular entity 19799
        polyatomic entity 19721
          molecule 19572
            cyclic compound 19379
              bicyclic compound 16961
                carbobicyclic compound 5822
                  indanes 86
                    (1R,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine 0
                    (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-2-phenylmethyl-4-hydroxy-5-[(2S)-4-(benzofuran-2-ylmethyl)-2-(tert-butylaminocarbonyl)piperazin-1-yl]pentanamide 0
                    (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-5-[(2S)-2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(phenylmethyl)pentanamide 0
                    (3R)-tetrahydrofuran-3-yl [(1S,2S)-1-benzyl-3-\{(2S)-2-benzyl-4-[(1R,2R)-2-(carbamoyloxy)-2,3-dihydro-1H-inden-1-yl]-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-2-hydroxypropyl]carbamate 0
                    (3S)-tetrahydrofuran-3-yl [(1S,2S)-3-\{(2S)-4-[(1R,3R)-3-(2-amino-2-oxoethyl)-2,3-dihydro-1H-inden-1-yl]-2-benzyl-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-1-benzyl-2-hydroxypropyl]carbamate 0
                    (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-3-(methylsulfonyl)-L-alanyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                    (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                    (R)-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                    (S,S)-trans-1-isopropyl-2,3,3,5-tetramethyl-6-succinylindane 0
                    (S,S)-trans-2-ethyl-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                    1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)-2-butanol 0
                    1-[2-[2-(2,3-dihydro-1H-inden-5-yloxy)ethoxy]ethyl]-1,2,4-triazole 0
                    2-(2,3-dichlorophenoxy)-N-(2,3-dihydro-1H-inden-5-yl)acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                    3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide + 0
                    4-Acetyl-6-tert-butyl-1,1-dimethylindane 2
                    5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine 0
                    5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarbohydrazide 0
                    5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime 0
                    6-methoxy indan-5-ol 0
                    Aprindine hydrochloride 0
                    Dimethyl (1R*,2S*,3S*)-2-carboxy-3-(3,4-dihydroxyphenyl)-2,3-dihydro-5,6-dihydroxy-1H-indene-1-acetate 0
                    GDC-0879 0
                    ICI 118551 30
                    Indanestrol 0
                    LSM-10937 0
                    LSM-11498 0
                    LSM-9123 0
                    LSM-9318 0
                    Ladostigil 0
                    Metabolite M6 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-2-[(2-nitro-3-pyridinyl)oxy]acetamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-2-methyl-3-nitrobenzamide 0
                    N-(2,3-dihydro-1H-inden-5-yl)-5-methyl-2-pyrazinecarboxamide 0
                    N-(2,3-dihydroinden-1-ylideneamino)-2,4-dimethylbenzamide 0
                    N-(2,3-dihydroinden-1-ylideneamino)-2-nitroaniline 0
                    N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine + 0
                    N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                    N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                    N-[(5-bromo-2-methoxyphenyl)methylideneamino]-5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarboxamide 0
                    N-[2-(2-methoxyphenoxy)ethyl]-2,3-dihydro-1H-indene-5-carboxamide 0
                    N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide 0
                    Zicronapine 0
                    allyl \{(1S)-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]-3-pyrrolidin-3-ylpropyl\}carbamate 0
                    aprindine 6
                    dimefadane 0
                    enrasentan 2
                    ethyl \{(1S)-5-amino-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]pentyl\}carbamate 0
                    glyhexamide 0
                    indacaterol 0
                    indan-1-ol + 3
                    indan-2-one oxime 0
                    indan-5-ol + 0
                    indanazoline 0
                    indane + 8
                    indanones + 4
                    inpyrfluxam 0
                    lignin cw compound-3045 0
                    pevonedistat 36
                    quadrangularin A 0
                    rasagiline 3
                    sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                    sulfamic acid [4-[4-(2,3-dihydro-1H-inden-1-ylamino)-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                    tolindate 0
                    traseolide + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19800
    subatomic particle 19799
      composite particle 19799
        hadron 19799
          baryon 19799
            nucleon 19799
              atomic nucleus 19799
                atom 19799
                  main group element atom 19698
                    p-block element atom 19698
                      carbon group element atom 19619
                        carbon group molecular entity 19619
                          organic molecular entity 19609
                            organic molecule 19549
                              organic cyclic compound 19343
                                carbocyclic compound 18316
                                  carbopolycyclic compound 17029
                                    carbobicyclic compound 5822
                                      indanes 86
                                        (1R,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine 0
                                        (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-2-phenylmethyl-4-hydroxy-5-[(2S)-4-(benzofuran-2-ylmethyl)-2-(tert-butylaminocarbonyl)piperazin-1-yl]pentanamide 0
                                        (2R,4S)-N-[(1S,2R)-2-hydroxyindan-1-yl]-5-[(2S)-2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(phenylmethyl)pentanamide 0
                                        (3R)-tetrahydrofuran-3-yl [(1S,2S)-1-benzyl-3-\{(2S)-2-benzyl-4-[(1R,2R)-2-(carbamoyloxy)-2,3-dihydro-1H-inden-1-yl]-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-2-hydroxypropyl]carbamate 0
                                        (3S)-tetrahydrofuran-3-yl [(1S,2S)-3-\{(2S)-4-[(1R,3R)-3-(2-amino-2-oxoethyl)-2,3-dihydro-1H-inden-1-yl]-2-benzyl-3-oxo-2,3-dihydro-1H-pyrrol-2-yl\}-1-benzyl-2-hydroxypropyl]carbamate 0
                                        (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-3-(methylsulfonyl)-L-alanyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                                        (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-(\{N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl\}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 0
                                        (R)-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                                        (S,S)-trans-1-isopropyl-2,3,3,5-tetramethyl-6-succinylindane 0
                                        (S,S)-trans-2-ethyl-1-isopropyl-3,3,5-trimethyl-6-succinylindane 0
                                        1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)-2-butanol 0
                                        1-[2-[2-(2,3-dihydro-1H-inden-5-yloxy)ethoxy]ethyl]-1,2,4-triazole 0
                                        2-(2,3-dichlorophenoxy)-N-(2,3-dihydro-1H-inden-5-yl)acetamide 0
                                        2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2,3-dihydro-1H-inden-2-yl)acetamide 0
                                        3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide + 0
                                        4-Acetyl-6-tert-butyl-1,1-dimethylindane 2
                                        5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine 0
                                        5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarbohydrazide 0
                                        5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime 0
                                        6-methoxy indan-5-ol 0
                                        Aprindine hydrochloride 0
                                        Dimethyl (1R*,2S*,3S*)-2-carboxy-3-(3,4-dihydroxyphenyl)-2,3-dihydro-5,6-dihydroxy-1H-indene-1-acetate 0
                                        GDC-0879 0
                                        ICI 118551 30
                                        Indanestrol 0
                                        LSM-10937 0
                                        LSM-11498 0
                                        LSM-9123 0
                                        LSM-9318 0
                                        Ladostigil 0
                                        Metabolite M6 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-2-yl)-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[oxo-(propan-2-ylamino)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-2-[(2-nitro-3-pyridinyl)oxy]acetamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-2-methyl-3-nitrobenzamide 0
                                        N-(2,3-dihydro-1H-inden-5-yl)-5-methyl-2-pyrazinecarboxamide 0
                                        N-(2,3-dihydroinden-1-ylideneamino)-2,4-dimethylbenzamide 0
                                        N-(2,3-dihydroinden-1-ylideneamino)-2-nitroaniline 0
                                        N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine + 0
                                        N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                                        N-(2-hydroxyindan-1-yl)-5-[2-(tert-butylaminocarbonyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-2-(1-phenylethyl)pentanamide 0
                                        N-[(5-bromo-2-methoxyphenyl)methylideneamino]-5-(2,3-dihydro-1H-inden-5-yloxymethyl)-2-furancarboxamide 0
                                        N-[2-(2-methoxyphenoxy)ethyl]-2,3-dihydro-1H-indene-5-carboxamide 0
                                        N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide 0
                                        Zicronapine 0
                                        allyl \{(1S)-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]-3-pyrrolidin-3-ylpropyl\}carbamate 0
                                        aprindine 6
                                        dimefadane 0
                                        enrasentan 2
                                        ethyl \{(1S)-5-amino-1-[(5-\{4-[(2,3-dihydro-1H-inden-2-ylamino)carbonyl]benzyl\}-1,2,4-oxadiazol-3-yl)carbonyl]pentyl\}carbamate 0
                                        glyhexamide 0
                                        indacaterol 0
                                        indan-1-ol + 3
                                        indan-2-one oxime 0
                                        indan-5-ol + 0
                                        indanazoline 0
                                        indane + 8
                                        indanones + 4
                                        inpyrfluxam 0
                                        lignin cw compound-3045 0
                                        pevonedistat 36
                                        quadrangularin A 0
                                        rasagiline 3
                                        sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                                        sulfamic acid [4-[4-(2,3-dihydro-1H-inden-1-ylamino)-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester 0
                                        tolindate 0
                                        traseolide + 0
paths to the root